There’s a real-life Prof Snape running Covid vaccine trial— and Harry Potter fans are excited
Warner Brother Studios

It’s safe to assume that having the same name as a famous fictional character could have its charms.

However, if you have a similar career to said famous fictional characters, it could probably get annoying.

That might be the case for Professor Matthew Snape, a vaccine researcher from the Oxford Vaccine Group who has the same last name and title as one of Harry Potter’s antagonists.

Currently, Professor Snape (the real-life one) is conducting a crucial Covid-19 vaccine trial in the United Kingdom.

Harry Potter fans didn’t hesitate to point out Snape’s name when the British news outlets began covering the vaccine trial in the week.

Read more:

Matthew Snape is the chief investigator of what is called the Com-Cov vaccine trial. This is a medical trial testing of the effectiveness of combining different Covid-19 vaccines on the same patient.

Over 800 people have already taken part in the research and have received either two doses of Astra Zeneca, Pfizer, or a “mix and match.”

It’s a significant study indeed, but people are more so fixated on the professor’s name, especially since his job ( sort of) involves mixing “magical potions” together.

Check out the reactions:

The University of Oxford also reconfirmed that this Snape is not a “Dark Arts” professor and is “a lot friendlier.”

The medical study tackles a fundamental question on people’s minds: what would happen if you take one type of Covid vaccination and then follow up with a different one?

According to BBC, Health experts believe that it is safe to combine different Covid-19. But are there any long-term effects, and is it effective against the virus?

The trial is set to expand with new volunteers and will run for a year. Matthew Snape hasn’t made any comment about the Harry Potter relation as of yet. But if we had to guess, it might have something to do with him being a busy scientist with more things on his mind to worry about.

Please log in or register to upvote this article
The Conversation (0)